IPP Bureau
Philips highlights AI-powered precision diagnosis portfolio at ECR 2022
By IPP Bureau - July 15, 2022
Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes
USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list
By IPP Bureau - July 14, 2022
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP
By IPP Bureau - July 14, 2022
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray
By IPP Bureau - July 14, 2022
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Bajaj Healthcare forays into the highly regulated - Opiate Processing Business for the GOI
By IPP Bureau - July 14, 2022
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
W.R. Grace to expand capacity at small-molecule API plant
By IPP Bureau - July 13, 2022
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Heathcare startup MedTel to raise around USD 10mn in Series A
By IPP Bureau - July 13, 2022
MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.
SRL Diagnostics launches fatty liver index
By IPP Bureau - July 13, 2022
An algorithm based testing for Fatty Liver Disease
Eversana partners with Compai Pharma to expand commercialisation services across APAC
By IPP Bureau - July 13, 2022
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada
By IPP Bureau - July 13, 2022
Plant is part of the company's CAD $30 million capital investment in the site
Athos announces research collaboration to advance precision medicine in inflammatory bowel disease
By IPP Bureau - July 13, 2022
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services
By IPP Bureau - July 13, 2022
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Biosyntia closes 1.5 million EUR round to launch world’s first bio-based vitamin B7
By IPP Bureau - July 12, 2022
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Zydus gets USFDA’s approval for Empagliflozin, Metformin Hydrochloride tablets
By IPP Bureau - July 12, 2022
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Healthcare Triangle announces $6.5 million private placement
By IPP Bureau - July 12, 2022
